Answers are grounded in this paper and cite their sources.
Relevance. Chronic refractory immune thrombocytopenia (ITP), especially associated with other autoimmune disorders, is a challenging clinical problem that requires an individualized therapeutic approach. Objective. To present and analyze a clinical case of chronic refractory ITP in an adolescent with comorbid antiphospholipid syndrome (APS) and to discuss modern treatment strategies for such patients. Materials and methods. A clinical observation of patient Kh., 14 years old, from November 2023 to September 2025 is described. Data from clinical examination, laboratory (complete blood count, immunological tests) and instrumental (bone marrow aspiration) methods, as well as specialist consultations were used. Results. A patient with typical ITP onset after ARVI developed a chronic, glucocorticoid-dependent and refractory course. Associated immune disorders (positive direct Coombs test, lupus anticoagulant, ANA) were identified, leading to the verification of APS. Prednisolone therapy induced remission but caused Cushing's syndrome. Monotherapy with romiplostim lost efficacy after 4 months. Stable remission (platelets 159×109/L) was achieved only with combined therapy of rituximab, mycophenolate mofetil and romiplostim. Conclusions. Management of refractory ITP associated with an overlapping autoimmune syndrome requires thorough immunological investigation and readiness to use combined immunosuppressive regimens. The presented case demonstrates the efficacy of the rituximab and mycophenolate mofetil combination in the setting of standard therapy failure. Keywords: immune thrombocytopenia, antiphospholipid syndrome, rituximab, mycophenolate mofetil, refractory disease, adolescent. For citation: Bazina I.B., Davydova Y.V., Molotkova S.A., Stepchenko S.S.
No takes yet. Share an insight, caveat, or question.
Bazina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: